Biocon Biologics secures license agreement for biosimilar launch in US

Biocon Biologics secures license agreement for biosimilar launch in US

In a landmark announcement, Biocon Biologics Ltd (BBL), a fully integrated global biosimilars company and a subsidiary of Biocon Ltd, revealed its settlement and license agreement with Janssen Biotech Inc., and Johnson & Johnson. This agreement signifies a crucial step forward, granting Biocon Biologics the license to commercialize its Bmab 1200, a proposed biosimilar to […]

Boston Scientific’s LUMINIZE RF Balloon Catheter shows promising results in AF-FICIENT I trial

Boston Scientific’s LUMINIZE RF Balloon Catheter shows promising results in AF-FICIENT I trial

Boston Scientific has announced that its LUMINIZE Radiofrequency (RF) Balloon Catheter, developed for isolating pulmonary veins (PVs) in atrial fibrillation (AF) treatment, has demonstrated positive safety and efficacy results in the AF-FICIENT I clinical trial. This new device marks an advancement in cardiac ablation technology and its ability to enhance treatment outcomes for patients with […]

Blackstone Life Sciences and Novartis launch Anthos Therapeutics to target high-risk cardiovascular diseases

Blackstone Life Sciences and Novartis launch Anthos Therapeutics to target high-risk cardiovascular diseases

In a strategic partnership aimed at advancing cardiovascular treatments, Blackstone Life Sciences has teamed up with Swiss pharmaceutical giant Novartis to create Anthos Therapeutics, a new biopharma company focused on developing innovative therapies for high-risk cardiovascular patients. With an initial capital infusion of $250 million, Blackstone Life Sciences will oversee the development and operational control […]

GlaxoSmithKline transfers rare disease gene therapy portfolio to Orchard Therapeutics in strategic deal

GlaxoSmithKline transfers rare disease gene therapy portfolio to Orchard Therapeutics in strategic deal

GlaxoSmithKline (GSK), a leading British pharmaceutical company, has entered into a significant agreement with Orchard Therapeutics, transferring its rare disease gene therapy drugs in exchange for a 19.9% equity stake and a seat on Orchard’s board. This move is part of GSK’s strategic initiative to refine its focus on core areas such as respiratory, HIV/infectious […]

EC approves Actelion’s Ledaga for treatment of cutaneous T-cell lymphoma

As per the Actelion recent news, the pharma’s Ledaga Chlormethine Gel 160 micrograms/g has been approved by the European Commission (EC) for CTCL MF treatment.

EC approves Actelion’s Ledaga for treatment of cutaneous T-cell lymphoma

The European Commission (EC) has granted marketing authorization to Actelion Pharmaceuticals for its innovative Ledaga Chlormethine Gel 160 micrograms/g, designed for the treatment of cutaneous T-cell lymphoma of the mycosis fungoides-type (CTCL MF). This approval marks a significant advancement in the treatment options available for this rare and often life-threatening immune system cancer. Breakthrough in […]

1 3 4 5